NeuroMetrix, Inc. NURO announced today that it entered into a
definitive securities purchase agreement with a healthcare dedicated
institutional investor in connection with a private placement of 13,800
shares of Series C convertible preferred stock at a price of $1,000 per
share, and two series of warrants to purchase an aggregate of
approximately 10.8 million shares of common stock at an exercise price
of $2.30 per share. The Company expects to receive gross proceeds from
the offering of $13.8 million. It is expected that approximately $6.3
million of the proceeds of the offering will be used to redeem 63,000
shares of Series B convertible preferred stock held by the healthcare
dedicated institutional investor and the balance of the proceeds will be
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in